Associations of urinary sodium excretion with cardiovascular events in individuals with and without hypertension: a pooled analysis of data from four studies

[1]  N. Graudal,et al.  Effects of low sodium diet versus high sodium diet on blood pressure, renin, aldosterone, catecholamines, cholesterol and triglyceride , 2011, The Cochrane database of systematic reviews.

[2]  Comentário a: «The SPRINT Research Group. A Randomized Trial of Intensive versus Standard Blood‐Pressure Control» , 2016 .

[3]  F. Cappuccio.  Sodium and cardiovascular disease , 2016, The Lancet.

[4]  S. Yusuf,et al.  Blood-Pressure Lowering in Intermediate-Risk Persons without Cardiovascular Disease. , 2016, The New England journal of medicine.

[5]  Bo Carlberg,et al.  Effect of antihypertensive treatment at different blood pressure levels in patients with diabetes mellitus: systematic review and meta-analyses , 2016 .

[6]  Jackson T. Wright,et al.  A Randomized Trial of Intensive versus Standard Blood-Pressure Control. , 2016, The New England journal of medicine.

[7]  N. Sun,et al.  Validation of the Spot Urine in Evaluating 24-Hour Sodium Excretion in Chinese Hypertension Patients. , 2015, American journal of hypertension.

[8]  Matthias Heinig,et al.  Cutaneous Na+ storage strengthens the antimicrobial barrier function of the skin and boosts macrophage-driven host defense. , 2015, Cell metabolism.

[9]  T. Kawasaki,et al.  Clinical application of the second morning urine method for estimating salt intake in patients with hypertension , 2015, Clinical and experimental hypertension.

[10]  K. Rahimi,et al.  Blood pressure lowering in type 2 diabetes: a systematic review and meta-analysis. , 2015, JAMA.

[11]  D. Mozaffarian,et al.  Sodium and cardiovascular disease. , 2014, The New England journal of medicine.

[12]  K. Kalantar-Zadeh,et al.  Plasma Renin Activity and Its Association With Ischemic Heart Disease, Congestive Heart Failure, and Cerebrovascular Disease in a Large Hypertensive Cohort , 2014, Journal of clinical hypertension.

[13]  Martin McKee,et al.  Cardiovascular risk and events in 17 low-, middle-, and high-income countries. , 2014, The New England journal of medicine.

[14]  M. Woodward,et al.  Blood pressure-lowering treatment based on cardiovascular risk: a meta-analysis of individual patient data , 2014, The Lancet.

[15]  Yu Chen,et al.  Global sodium consumption and death from cardiovascular causes. , 2014 .

[16]  S. Yusuf,et al.  Association of urinary sodium and potassium excretion with blood pressure. , 2014, The New England journal of medicine.

[17]  Majid Ezzati,et al.  Global sodium consumption and death from cardiovascular causes. , 2014, The New England journal of medicine.

[18]  S. Yusuf,et al.  Urinary sodium and potassium excretion, mortality, and cardiovascular events. , 2014, The New England journal of medicine.

[19]  S. Oparil,et al.  Low sodium intake--cardiovascular health benefit or risk? , 2014, The New England journal of medicine.

[20]  S. Yusuf,et al.  Validation and comparison of three formulae to estimate sodium and potassium excretion from a single morning fasting urine compared to 24-h measures in 11 countries , 2014, Journal of hypertension.

[21]  F. Luft,et al.  Taking another "look" at sodium. , 2014, The Canadian journal of cardiology.

[22]  S. Sharp,et al.  Estimated urinary sodium excretion and risk of heart failure in men and women in the EPIC‐Norfolk study , 2014, European journal of heart failure.

[23]  G. Jürgens,et al.  Compared with usual sodium intake, low- and excessive-sodium diets are associated with increased mortality: a meta-analysis. , 2014, American Journal of Hypertension.

[24]  M. M. Joosten,et al.  Sodium Excretion and Risk of Developing Coronary Heart Disease , 2014, Circulation.

[25]  D. Caldeira,et al.  [What is the benefit of salt reduction on blood pressure? Assessment of the Cochrane Review: Effect of longer-term modest salt reduction on blood pressure. He FJ, Li J, Macgregor GA. Cochrane Database Syst Rev. 2013 Apr 30;4:CD004937]. , 2013, Acta medica portuguesa.

[26]  Joel C Geerling,et al.  Normal range of human dietary sodium intake: a perspective based on 24-hour urinary sodium excretion worldwide. , 2013, American journal of hypertension.

[27]  S. Yusuf,et al.  Prospective Urban Rural Epidemiology (PURE) study: Baseline characteristics of the household sample and comparative analyses with national data in 17 countries. , 2013, American heart journal.

[28]  Martin McKee,et al.  Prevalence, awareness, treatment, and control of hypertension in rural and urban communities in high-, middle-, and low-income countries. , 2013, JAMA.

[29]  R. Conwit,et al.  Blood-pressure targets in patients with recent lacunar stroke: the SPS3 randomised trial , 2013, The Lancet.

[30]  S. N. Thornton,et al.  Salt in health and disease--a delicate balance. , 2013, The New England journal of medicine.

[31]  Wei Li,et al.  Prevalence of a healthy lifestyle among individuals with cardiovascular disease in high-, middle- and low-income countries: The Prospective Urban Rural Epidemiology (PURE) study. , 2013, JAMA.

[32]  B. Johannes,et al.  Long-term space flight simulation reveals infradian rhythmicity in human Na(+) balance. , 2013, Cell metabolism.

[33]  Nish Chaturvedi,et al.  Cardiorenal end points in a trial of aliskiren for type 2 diabetes. , 2012, The New England journal of medicine.

[34]  S. Yusuf,et al.  Glucose levels are associated with cardiovascular disease and death in an international cohort of normal glycaemic and dysglycaemic men and women: the EpiDREAM cohort study , 2011, European journal of preventive cardiology.

[35]  H. Rao.  Use of secondary prevention drugs for cardiovascular disease in the community in high-income, middle-income, and low-income countries (the PURE Study): a prospective epidemiological survey , 2012 .

[36]  W. Elliott.  Urinary Sodium and Potassium Excretion and Risk of Cardiovascular Events , 2012 .

[37]  S. Yusuf,et al.  Urinary sodium and potassium excretion and risk of cardiovascular events. , 2011, JAMA.

[38]  S. Yusuf,et al.  Use of secondary prevention drugs for cardiovascular disease in the community in high-income, middle-income, and low-income countries (the PURE Study): a prospective epidemiological survey , 2011, The Lancet.

[39]  S. Yusuf,et al.  Plasma renin activity predicts cardiovascular mortality in the Heart Outcomes Prevention Evaluation (HOPE) study. , 2011, European heart journal.

[40]  J. Staessen,et al.  Fatal and nonfatal outcomes, incidence of hypertension, and blood pressure changes in relation to urinary sodium excretion. , 2011, JAMA.

[41]  D. Gordin,et al.  The Association Between Dietary Sodium Intake, ESRD, and All-Cause Mortality in Patients With Type 1 Diabetes , 2011, Diabetes Care.

[42]  Merlin C. Thomas,et al.  Dietary Salt Intake and Mortality in Patients With Type 2 Diabetes , 2011, Diabetes Care.

[43]  M. Woodward,et al.  The effects of blood pressure reduction and of different blood pressure-lowering regimens on major cardiovascular events according to baseline blood pressure: meta-analysis of randomized trials , 2011, Journal of hypertension.

[44]  Kevin A Peterson,et al.  Effects of Intensive Blood-Pressure Control in Type 2 Diabetes Mellitus , 2011 .

[45]  G. Bakris,et al.  Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. , 2008, The New England journal of medicine.

[46]  S. Yusuf,et al.  Effects of aspirin plus extended-release dipyridamole versus clopidogrel and telmisartan on disability and cognitive function after recurrent stroke in patients with ischaemic stroke in the Prevention Regimen for Effectively Avoiding Second Strokes (PRoFESS) trial: a double-blind, active and placebo , 2008, The Lancet Neurology.

[47]  S. Yusuf,et al.  Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial , 2008, The Lancet.

[48]  W. Ahmad.  Effect of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomized controlled trial: The Telmisartan Randomised Assessment Study in ACE intolerant subjects with cardiovascular Disease (TRANSCEND) , 2008 .

[49]  S. Yusuf,et al.  Telmisartan, ramipril, or both in patients at high risk for vascular events. , 2008, The New England journal of medicine.

[50]  A. Loewy,et al.  Central regulation of sodium appetite , 2008, Experimental physiology.

[51]  J. Marin-Neto.  Telmisartan, ramipril, or both in patients at high risk for vascular events , 2008 .

[52]  R. Collins,et al.  Blood cholesterol and vascular mortality by age, sex, and blood pressure: a meta-analysis of individual data from 61 prospective studies with 55 000 vascular deaths , 2007, The Lancet.

[53]  B. Davis,et al.  Abstract 2734: Heart Failure with Preserved and Impaired Left Ventricular Systolic Function in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) , 2006 .

[54]  M. Laakso,et al.  Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial , 2006, The Lancet.

[55]  T. Sugawara,et al.  Effectiveness of a Spot Urine Method in Evaluating Daily Salt Intake in Hypertensive Patients Taking Oral Antihypertensive Drugs , 2006, Hypertension Research.

[56]  G. MacGregor,et al.  Effect of longer-term modest salt reduction on blood pressure. , 2000, The Cochrane database of systematic reviews.

[57]  C. Zoccali,et al.  Plasma Norepinephrine Predicts Survival and Incident Cardiovascular Events in Patients With End-Stage Renal Disease , 2002, Circulation.

[58]  Kukin Ml.  The Heart Outcomes Prevention Evaluation Study. , 2001, Current cardiology reports.

[59]  Frank E. Harrell,et al.  Regression Modeling Strategies: With Applications to Linear Models, Logistic Regression, and Survival Analysis , 2001 .

[60]  B. Neal.  The Blood Pressure Lowering Treatment Trialists' Collaboration , 2001 .

[61]  Barry R. Davis,et al.  Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). ALLHAT Collaborative Research Group. , 2000, JAMA.

[62]  S. Yusuf,et al.  Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. , 2000 .

[63]  C R Benedict,et al.  Prognostic significance of plasma norepinephrine in patients with asymptomatic left ventricular dysfunction. SOLVD Investigators. , 1996, Circulation.

[64]  K. Itoh,et al.  A SIMPLE METHOD FOR ESTIMATING 24 H URINARY SODIUM AND POTASSIUM EXCRETION FROM SECOND MORNING VOIDING URINE SPECIMEN IN ADULTS , 1993, Clinical and experimental pharmacology & physiology.

[65]  M. Weinberger.  Salt sensitivity as a predictor of hypertension. , 1991, American journal of hypertension.

[66]  J. Laragh,et al.  Association of the renin-sodium profile with the risk of myocardial infarction in patients with hypertension. , 1991, The New England journal of medicine.

[67]  R. Collins,et al.  Blood pressure, stroke, and coronary heart disease Part 2, short-term reductions in blood pressure: overview of randomised drug trials in their epidemiological context , 1990, The Lancet.

[68]  R. Collins,et al.  Blood pressure, stroke, and coronary heart disease Part 1, prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias , 1990, The Lancet.

[69]  J. Cohn,et al.  Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure. , 1984, The New England journal of medicine.

[70]  J. Neel,et al.  Blood Pressure, Sodium Intake, and Sodium Related Hormones in the Yanomamo Indians, a “No‐salt” Culture , 1975, Circulation.

[71]  J. Laragh,et al.  Essential hypertension: renin and aldosterone, heart attack and stroke. , 1972, The New England journal of medicine.